Clinical Trial Update: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial in MMR-deficient endometrial cancer is evaluating first-line chemotherapy versus dostarlimab. The study is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Chemotherapy (unspecified regimens)
• Dostarlimab (dostarlimab)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Endometrial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING